Ujin Pharma Ltd. IPO Details
Ujin Pharma was incorporated on November 15, 2019. The company is engaged in the distribution and supply of a diversified portfolio of chemicals, pharmaceutical raw materials, and nutraceuticals, serving customers across multiple industries. Leveraging over two decades of industry experience, it provides end-to-end procurement, sourcing, logistics, and supply chain solutions through a strong network of domestic and international suppliers
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 19.2 M | - | - | ₹0 | DRHP DOC |
Ujin Pharma issue details
Ujin Pharma has 19.2 M shares on offer
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Ujin Pharma IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Ujin Pharma NUMBER OF SHARES ON OFFER
Ujin Pharma FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| 9MFY26 | 1,511.3 | 25.5 | -30.7 | -31.8 | - |
| FY25 | 1,628.8 | 14.3 | 3.0 | 2.9 | 2.2% |
| FY24 | 1,490.9 | 16.0 | -66.5 | -66.5 | 2.0% |
| FY23 | 1,425.8 | 10.0 | -19.0 | -19.1 | 0.9% |
Ujin Pharma INFORMATION ON IPO ISSUE
About Ujin Pharma
Ujin Pharma was incorporated on November 15, 2019. The company is engaged in the distribution and supply of a diversified portfolio of chemicals, pharmaceutical raw materials, and nutraceuticals, serving customers across multiple industries. Leveraging over two decades of industry experience, it provides end-to-end procurement, sourcing, logistics, and supply chain solutions through a strong network of domestic and international suppliers
Object of the Issue
- Investment in Altra Agro-Chem Private Limited, their associate company, by way of subscription to equity shares for making it its subsidiary
- Investment in Altra Pharma-Chem Private Limited, their associate company, by way of subscription to equity shares for making it its subsidiary
- Repayment or pre-payment, in part or full of certain borrowings availed by the company from financial institutions
- General corporate purposes
Ujin Pharma - PROMOTERS
| Name |
|---|
| Jinesh Rasiklal Sheth |
| Umang Ketan Mehta |
| Neha Umang Mehta |
Ujin Pharma - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Jinesh Rasiklal Sheth | Managing Director |
| Umang Ketan Mehta | Chairman & Whole-Time Director |
| Neha Umang Mehta | Non- Executive Director |
| Vratika Jain | Non- Executive Independent Director |
| Ravi Sharma | Non- Executive Independent Director |
| Anand Malpani | Non- Executive Independent Director |
Ujin Pharma Book Running Lead Manager
SMC Capitals Limited
ujin.ipo@smccapitals.com
Marwadi Chandarana Intermediaries Brokers Private Limited
mb@marwadichandarana.com
Ujin Pharma Registrar to the Offer
KFin Technologies Limited
ujinpharma.ipo@kfintech.com
Ujin Pharma Strengths
Diversified product portfolio
The company offers a diversified portfolio of over 100 chemical products, including solvents, specialty chemicals, acids, monomers, pharmaceutical raw materials, and nutraceuticals, serving customers across multiple industries. Its broad product range reduces dependence on any single sector while enabling it to meet diverse customer requirements through a comprehensive distribution platform
Client relationship
The company has established strong relationships with customers across industries such as pharmaceuticals, agrochemicals, specialty chemicals, petrochemicals, and industrial manufacturing. Its integrated sourcing, procurement, logistics, and supply chain capabilities enable it to deliver reliable, timely, and cost-effective chemical supply solutions tailored to customer requirements
Distribution network
The company’s distribution network is supported by strategically located warehouses and storage facilities in key logistics hubs such as Bhiwandi and Kandla, enabling efficient inventory management and product distribution across India. Its warehousing, import handling, and logistics coordination capabilities support the timely and reliable supply of chemical products to customers across multiple industries
Ujin Pharma Risks
Foreign currency fluctuation risk
The company is exposed to foreign exchange risk due to its import and export activities, with revenues, expenses, receivables, and payables linked to foreign currencies. Adverse currency fluctuations, particularly depreciation of the Indian Rupee, could increase procurement costs, impact profitability, and adversely affect financial performance
Competition
The company operates in a highly competitive chemical distribution and processing industry, facing competition from distributors, manufacturers, traders, and specialty chemical companies. Any inability to compete effectively on pricing, product availability, quality, or supply reliability could adversely impact its market position, revenue, and profitability
Material handling risks
The company’s operations involve inherent risks related to the handling, storage, transportation, and processing of chemical products, which may result in accidents, inventory losses, environmental incidents, or regulatory actions. Any significant operational disruption or uninsured loss, including incidents similar to the fire experienced at its processing facility, could adversely affect the company’s business, financial performance, and cash flows
IPO FAQs
The promoters of the company are Jinesh Rasiklal Sheth, Umang Ketan Mehta and Neha Umang Mehta.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.